Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration‐resistant prostate cancer treated with Radium‐223-Reference-Cited by-同舟云学术

Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration‐resistant prostate cancer treated with Radium‐223

Published:2021-07-13 Issue:17 Volume:10 Page:5775-5782
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Al‐Ezzi Esmail M.¹,Alqaisi Husam A.¹,Iafolla Marco A. J.¹,Wang Lisa²,Sridhar Srikala S.¹,Sacher Adrian G.¹,Fallah‐Rad Nazanin¹,Jiang Di M.¹^ORCID,Watson Geoffrey A.¹,Catton Charles N.³,Warde Padraig R.³,Hamilton Rob J.⁴,Fleshner Neil E.⁴,Zlotta Alexandre R.⁴,Hansen Aaron R.¹^ORCID

Affiliation:

1. Division of Medical Oncology and Hematology Princess Margaret Cancer Centre Toronto ON Canada

2. Department of Biostatistics Princess Margaret Cancer Centre Toronto ON Canada

3. Department of Radiation Oncology Princess Margaret Cancer Centre Toronto ON Canada

4. Division of Urologic Oncology Princess Margaret Cancer Centre Toronto ON Canada

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4125

Reference28 articles.

1. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods

2. Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer

3. Preventing Bone Complications in Advanced Prostate Cancer

4. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

5. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The prognostic value of Eastern Cooperative Oncology Group performance status on overall survival among patients with metastatic prostate cancer: a systematic review and meta-analysis;Frontiers in Oncology;2023-12-15

2. Low Alanine Aminotransferase, as a Marker of Sarcopenia and Frailty, Is Associated with Shorter Survival Among Prostate Cancer Patients and Survivors. A Retrospective Cohort Analysis of 4064 Patients;European Urology Open Science;2023-09

3. Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer;Frontiers in Medicine;2022-12-22

4. Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer;Expert Review of Anticancer Therapy;2022-11-02

5. Prognostic Value of the BIO-Ra Score in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223 after the European Medicines Agency Restricted Use: Secondary Investigations of the Multicentric BIO-Ra Study;Cancers;2022-03-29